Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin MNA in Nodular Basal Cell Carcinoma
NCT06608238Phase 2Completed
- Sponsor
- SkinJect
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of doxorubicin in basal cell carcinoma (nodular) (BCC), sponsored by SkinJect. Started Sep 2024; status: completed.
02
Drugs
doxorubicin
03
Conditions
basal cell carcinoma (nodular) (BCC)
Beyond the preview
Go deeper on NCT06608238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608238.